Cardinal buys up Alaris shares:
This article was originally published in Clinica
Executive Summary
Cardinal Health has completed its tender offer for all outstanding shares of common stock of Alaris Medical Systems. As previously announced, Cardinal purchased the shares at a price of $22.35 each in cash as part of its plan to acquire San Diego, California-based Alaris. The final steps to completing the merger - in which the developer of needle-free valves and systems will become a wholly-owned Cardinal subsidiary - is going ahead despite the dark cloud of litigation hanging over Alaris. At the end of last month, ICU Medical had filed a patent lawsuit against San Diego, California-based Alaris concerning the latter's SmartSite and SmartSite Plus needle-free valves and systems (see Clinica No 1113, p 12).
You may also be interested in...
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.